Drugs / OZUREPRUBART
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07513857 | May 2026 → Jul 2027 expected | allergic disease | Jemincare | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05449535 | May 2022 → Jan 2023 | — | Jemincare | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06509334 | Aug 2024 → Jul 2026 overdue | chronic idiopathic urticaria | Jemincare | Recruiting | No outcome recorded |
| Phase 2 | NCT06438757 | Jun 2024 → Nov 2025 | allergic asthma | Jemincare | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07402213 | Mar 2026 → Jun 2027 expected | chronic idiopathic urticaria | Jemincare | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07459452 Comparator | Apr 2026 → Oct 2027 expected | perennial allergic rhinitis | Jemincare | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OZUREPRUBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068159 ↗ |
| Known as | JYB1904 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07513857 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068159 ↗ |
| Route | Subcutaneous | “subcutaneous injection in the deltoid region of the upper arm.” NCT05449535 ↗ |